Q1 2026 Nykode Therapeutics ASA Earnings Call Transcript
Key Points
- Nykode Therapeutics AS (STU:5VB) is well-capitalized with funding secured until 2028, providing financial stability for ongoing and future projects.
- The company has made significant progress with its lead asset, abi-suva, including dosing the first patient in the randomized Phase II trial, marking a transition from preparation to execution.
- Interim data from trials involving abi-suva in combination with KEYTRUDA showed an objective response rate of 39%, which is a significant improvement over the standard of care.
- Nykode is leveraging AI and machine learning extensively in its VB10.NEO program, enhancing the selection of neoantigens and optimizing constructs.
- The company is actively expanding its clinical trial footprint, with approvals in 7 EU countries and plans to open additional sites to ensure timely patient recruitment.
- Nykode reported a net loss of $4.1 million for the first quarter of 2026, compared to a net loss of $1.4 million for the same period in 2025.
- The company faces competition in patient recruitment, particularly from BioNTech, which is conducting a trial targeting the same patient population.
- There is uncertainty regarding the pending tax case, which, if not resolved favorably, could impact the company's cash runway.
- The company has not provided specific guidance on patient recruitment numbers by the end of 2026, creating some uncertainty about trial progress.
- Nykode's strategy for its VB10.NEO program is contingent on potential positive data from competitors, which introduces an element of dependency on external factors.
Greetings, and welcome to the Nykode Therapeutics Q1 2026 Financial Results Presentation. (Operator Instructions) As a reminder, this conference is being recorded.
It's now my pleasure to turn the call over to Nykode's, CEO, Michael Engsig. Please go ahead, sir.
Thank you very much, Kevin. And also from my side, a very warm welcome to all our listeners to this our first quarter webcast on this beautiful summer day in Oslo. A quick look at our forward-looking statements, which I think you are all familiar. On that basis, we will move forward. As usual, it is a pleasure to have with me today here, Agnete Fredriksen, our Co-Founder, Chief Scientific Officer and Head of Business Development; as well as Harald Gurvin, our Chief Financial Officer.
We will take you through the highlights of the quarter, a little bit deep dive into some of the data and of course, the financial numbers also.
So for the new listeners, a very quick recap. Nykode is a clinical-stage immunotherapy
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
